Home / GIFLF : OTC

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does GIFLF make money? Does GIFLF have pricing power? What's the Earnings Whisper? Will GIFLF profit more as the business scales? What is GIFLF's management track record? Is GIFLF's current price justified?

Grifols, S.A.

$11.33 -$0.33 (-2.83%)

OTC · 11 Sep 2026 20:00 UTC

Previous Close

$11.33

Day Range

$10.45$11.33

Year Range

$10.13$13.9

Market Cap

7.71B

AVG Volume

373

Trailing/Forward PE

14.66/10.4

PEG ratio

0.49

Dividend Yield

0.84%

Next Earnings Date

2026-11-10

Primary Exchange

Other OTC

Revenue (EUR) · TTM

GIFLF Revenue (EUR) · TTM by quarter
Period	Revenue (EUR) · TTM
26 Q2	7.43B
26 Q1	7.44B
25 Q4	7.52B
25 Q3	7.52B
25 Q2	7.45B
25 Q1	7.37B
24 Q4	7.21B
24 Q3	7.01B
24 Q2	6.81B
24 Q1	6.66B

Net Income (EUR) · TTM

GIFLF Net Income (EUR) · TTM by quarter
Period	Net Income (EUR) · TTM
26 Q2	452.35M
26 Q1	415.41M
25 Q4	401.86M
25 Q3	372.72M
25 Q2	297.45M
25 Q1	195.22M
24 Q4	156.92M
24 Q3	143.94M
24 Q2	151.8M
24 Q1	196.99M

Operating Income (EUR) · TTM

GIFLF Operating Income (EUR) · TTM by quarter
Period	Operating Income (EUR) · TTM
26 Q2	1.24B
26 Q1	1.26B
25 Q4	1.28B
25 Q3	1.37B
25 Q2	1.31B
25 Q1	1.26B
24 Q4	1.19B
24 Q3	1.06B
24 Q2	991.41M
24 Q1	945.74M

EBITDA (EUR) · TTM

GIFLF EBITDA (EUR) · TTM by quarter
Period	EBITDA (EUR) · TTM
26 Q2	1.62B
26 Q1	1.43B
25 Q4	1.48B
25 Q3	1.55B
25 Q2	1.56B
25 Q1	1.58B
24 Q4	1.53B
24 Q3	1.75B
24 Q2	1.64B
24 Q1	1.6B

Cash Flows (EUR) · TTM

GIFLF Cash Flows (EUR) · TTM by quarter
Period	Cash Flows (EUR) · TTM
26 Q2	766.75M
26 Q1	753.77M
25 Q4	781.87M
25 Q3	808.56M
25 Q2	768.57M
25 Q1	895.92M
24 Q4	606.63M
24 Q3	288.04M
24 Q2	162.08M
24 Q1	-126.34M

EPS (EUR) · TTM

GIFLF EPS (EUR) · TTM by quarter
Period	EPS (EUR) · TTM
26 Q2	0.66
26 Q1	0.6
25 Q4	0.59
25 Q3	0.55
25 Q2	0.43
25 Q1	0.28
24 Q4	0.22
24 Q3	0.2
24 Q2	0.22
24 Q1	0.29

Expenses (EUR) · TTM

GIFLF Expenses (EUR) · TTM by quarter
Period	Expenses (EUR) · TTM
26 Q2	1.86B
26 Q1	1.8B
25 Q4	1.84B
25 Q3	1.87B
25 Q2	1.92B
25 Q1	1.9B
24 Q4	1.89B
24 Q3	1.93B
24 Q2	1.88B
24 Q1	1.88B

Shares Outstanding (EUR) · TTM

GIFLF Shares Outstanding (EUR) · TTM by quarter
Period	Shares Outstanding (EUR) · TTM
26 Q2	128.95M
26 Q1	128.95M
25 Q4	128.95M
25 Q3	0
25 Q2	0
25 Q1	0
24 Q4	0
24 Q3	0
24 Q2	0
24 Q1	0

Dividends (EUR)

GIFLF Dividends (EUR) by quarter
Period	Dividends (EUR)
Jul 26	0.09
Aug 25	0.18
Jun 21	0.45
Oct 20	0.19
Dec 19	0.22
Jun 19	0.16
Nov 18	0.23
Jun 18	0.24
Dec 17	0.21
May 17	0.15

Employee Count

GIFLF Employee Count by quarter
Period	Employee Count
2025	25.25K
2023	23.82K
2022	26.31K
2021	23.23K
2020	23.66K
2019	24K
2018	21.23K
2017	18.3K
2016	14.88K
2015	14.74K

PE Ratio

GIFLF PE Ratio by quarter
Period	PE Ratio
Sep 26	14.69
Sep 26	14.35
Aug 26	15.27
Aug 26	15.15
Aug 26	15.29
Aug 26	15.3
Jul 26	13.37
Jul 26	14.76
Jul 26	14.68
Jul 26	14.85
Jul 26	15.03
Jun 26	15.71
Jun 26	15.6
Jun 26	15.68
Jun 26	16.51
May 26	16.32
May 26	16.4
May 26	15.55
May 26	15.35
May 26	15.43
Apr 26	15.43
Apr 26	15.37
Apr 26	15.42
Apr 26	19.12
Mar 26	19.18
Mar 26	19.08
Mar 26	19.3
Mar 26	19
Feb 26	18.67
Feb 26	18.07
Feb 26	17.93
Feb 26	18.01
Jan 26	17.96
Jan 26	17.99
Jan 26	18.35
Jan 26	18.29
Jan 26	18.16
Dec 25	18.08
Dec 25	18.18
Dec 25	18.13
Dec 25	18.28
Nov 25	18.35
Nov 25	18.49
Nov 25	21.83
Nov 25	21.94
Oct 25	27.79
Oct 25	27.66
Oct 25	27.61
Oct 25	27.67
Oct 25	27.39
Sep 25	27.5
Sep 25	27.4
Sep 25	27.43
Sep 25	27.45
Aug 25	27.53
Aug 25	27.44
Aug 25	27.48
Aug 25	27.64
Aug 25	27.77
Jul 25	41.26
Jul 25	41.97
Jul 25	34.14
Jul 25	33.94
Jun 25	34.06
Jun 25	37.19
Jun 25	33.03
Jun 25	33.49
May 25	32.08
May 25	32.03
May 25	26.53
May 25	32.76
May 25	32.61
Apr 25	32.42
Apr 25	32.41
Apr 25	32.42
Apr 25	37.69
Mar 25	53.73
Mar 25	53.84
Mar 25	53.47
Mar 25	53.76
Feb 25	56.13
Feb 25	46.31
Feb 25	46.18
Feb 25	43.16
Jan 25	43.04
Jan 25	44.21
Jan 25	47.93
Jan 25	48.04
Jan 25	47.74
Dec 24	44.78
Dec 24	44.76
Dec 24	44.44
Dec 24	42.32
Nov 24	51.06
Nov 24	50.42
Nov 24	52.81
Nov 24	51.8
Nov 24	49.82
Oct 24	50.74
Oct 24	50.42

Free Cash Flow Yield

GIFLF Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	11.54%
Sep 26	11.82%
Aug 26	11.1%
Aug 26	11.19%
Aug 26	11.08%
Aug 26	11.08%
Jul 26	12.67%
Jul 26	12.29%
Jul 26	12.36%
Jul 26	12.22%
Jul 26	12.08%
Jun 26	12.39%
Jun 26	12.47%
Jun 26	12.41%
Jun 26	11.78%
May 26	11.92%
May 26	11.86%
May 26	12.51%
May 26	12.68%
May 26	12.61%
Apr 26	12.61%
Apr 26	12.66%
Apr 26	12.62%
Apr 26	10.18%
Mar 26	10.15%
Mar 26	10.2%
Mar 26	10.08%
Mar 26	10.24%
Feb 26	10.42%
Feb 26	12.01%
Feb 26	12.1%
Feb 26	12.04%
Jan 26	12.08%
Jan 26	12.06%
Jan 26	11.82%
Jan 26	11.86%
Jan 26	11.95%
Dec 25	12%
Dec 25	11.93%
Dec 25	11.97%
Dec 25	11.87%
Nov 25	11.82%
Nov 25	11.73%
Nov 25	9.94%
Nov 25	9.89%
Oct 25	9.3%
Oct 25	9.34%
Oct 25	9.36%
Oct 25	9.34%
Oct 25	9.43%
Sep 25	9.4%
Sep 25	9.43%
Sep 25	9.42%
Sep 25	9.41%
Aug 25	9.39%
Aug 25	9.42%
Aug 25	9.4%
Aug 25	9.35%
Aug 25	9.3%
Jul 25	11.12%
Jul 25	10.93%
Jul 25	13.44%
Jul 25	13.52%
Jun 25	13.48%
Jun 25	12.34%
Jun 25	13.89%
Jun 25	13.7%
May 25	14.3%
May 25	14.33%
May 25	17.3%
May 25	11.8%
May 25	11.85%
Apr 25	11.93%
Apr 25	11.93%
Apr 25	11.92%
Apr 25	10.26%
Mar 25	3.72%
Mar 25	3.72%
Mar 25	3.74%
Mar 25	3.72%
Feb 25	3.56%
Feb 25	4.32%
Feb 25	4.33%
Feb 25	4.64%
Jan 25	4.65%
Jan 25	4.53%
Jan 25	4.18%
Jan 25	4.17%
Jan 25	4.19%
Dec 24	2.38%
Dec 24	2.39%
Dec 24	2.4%
Dec 24	2.52%
Nov 24	2.09%
Nov 24	2.12%
Nov 24	2.02%
Nov 24	2.06%
Nov 24	2.14%
Oct 24	2.1%
Oct 24	2.12%

Price to Sales

GIFLF Price to Sales by quarter
Period	Price to Sales
Sep 26	0.89
Sep 26	0.87
Aug 26	0.93
Aug 26	0.92
Aug 26	0.93
Aug 26	0.93
Jul 26	0.81
Jul 26	0.82
Jul 26	0.82
Jul 26	0.83
Jul 26	0.84
Jun 26	0.84
Jun 26	0.83
Jun 26	0.84
Jun 26	0.88
May 26	0.87
May 26	0.88
May 26	0.83
May 26	0.82
May 26	0.82
Apr 26	0.82
Apr 26	0.82
Apr 26	0.82
Apr 26	1.02
Mar 26	1.02
Mar 26	1.02
Mar 26	1.03
Mar 26	1.01
Feb 26	1
Feb 26	0.9
Feb 26	0.89
Feb 26	0.89
Jan 26	0.89
Jan 26	0.89
Jan 26	0.91
Jan 26	0.91
Jan 26	0.9
Dec 25	0.9
Dec 25	0.9
Dec 25	0.9
Dec 25	0.91
Nov 25	0.91
Nov 25	0.92
Nov 25	1.08
Nov 25	1.09
Oct 25	1.11
Oct 25	1.11
Oct 25	1.1
Oct 25	1.11
Oct 25	1.09
Sep 25	1.1
Sep 25	1.09
Sep 25	1.1
Sep 25	1.1
Aug 25	1.1
Aug 25	1.1
Aug 25	1.1
Aug 25	1.1
Aug 25	1.11
Jul 25	1.09
Jul 25	1.11
Jul 25	0.9
Jul 25	0.9
Jun 25	0.9
Jun 25	0.98
Jun 25	0.87
Jun 25	0.89
May 25	0.85
May 25	0.85
May 25	0.7
May 25	0.71
May 25	0.71
Apr 25	0.71
Apr 25	0.71
Apr 25	0.71
Apr 25	0.82
Mar 25	1.1
Mar 25	1.11
Mar 25	1.1
Mar 25	1.1
Feb 25	1.15
Feb 25	0.95
Feb 25	0.95
Feb 25	0.89
Jan 25	0.88
Jan 25	0.91
Jan 25	0.98
Jan 25	0.99
Jan 25	0.98
Dec 24	1
Dec 24	1
Dec 24	0.99
Dec 24	0.94
Nov 24	1.14
Nov 24	1.12
Nov 24	1.18
Nov 24	1.15
Nov 24	1.11
Oct 24	1.13
Oct 24	1.12

EV/EBITDA

GIFLF EV/EBITDA by quarter
Period	EV/EBITDA
Sep 26	9.05
Sep 26	8.95
Aug 26	9.21
Aug 26	9.17
Aug 26	9.21
Aug 26	9.22
Jul 26	8.68
Jul 26	10.54
Jul 26	10.52
Jul 26	10.57
Jul 26	10.62
Jun 26	10.2
Jun 26	10.17
Jun 26	10.19
Jun 26	10.42
May 26	10.37
May 26	10.39
May 26	10.16
May 26	10.1
May 26	10.13
Apr 26	10.13
Apr 26	10.11
Apr 26	10.12
Apr 26	11.13
Mar 26	11.14
Mar 26	11.12
Mar 26	11.18
Mar 26	11.09
Feb 26	11
Feb 26	4.52
Feb 26	4.49
Feb 26	4.51
Jan 26	4.49
Jan 26	4.5
Jan 26	4.59
Jan 26	4.57
Jan 26	4.54
Dec 25	4.52
Dec 25	4.55
Dec 25	4.53
Dec 25	4.57
Nov 25	4.59
Nov 25	4.62
Nov 25	5.43
Nov 25	5.45
Oct 25	10.61
Oct 25	10.59
Oct 25	10.58
Oct 25	10.59
Oct 25	10.54
Sep 25	10.56
Sep 25	10.54
Sep 25	10.54
Sep 25	10.55
Aug 25	10.56
Aug 25	10.54
Aug 25	10.55
Aug 25	10.58
Aug 25	10.61
Jul 25	10.79
Jul 25	10.88
Jul 25	9.91
Jul 25	9.89
Jun 25	9.9
Jun 25	10.29
Jun 25	9.78
Jun 25	9.83
May 25	9.66
May 25	9.65
May 25	8.97
May 25	9.32
May 25	9.3
Apr 25	9.28
Apr 25	9.28
Apr 25	9.28
Apr 25	9.82
Mar 25	9.59
Mar 25	9.59
Mar 25	9.56
Mar 25	9.59
Feb 25	9.78
Feb 25	8.97
Feb 25	8.96
Feb 25	8.72
Jan 25	8.71
Jan 25	8.8
Jan 25	9.11
Jan 25	9.12
Jan 25	9.09
Dec 24	9.3
Dec 24	9.3
Dec 24	9.27
Dec 24	9.07
Nov 24	9.88
Nov 24	9.82
Nov 24	10.04
Nov 24	9.95
Nov 24	9.77
Oct 24	9.85
Oct 24	9.82

Price/Operating Cashflow

GIFLF Price/Operating Cashflow by quarter
Period	Price/Operating Cashflow
Sep 26	6.08
Sep 26	5.93
Aug 26	6.32
Aug 26	6.27
Aug 26	6.33
Aug 26	6.33
Jul 26	5.53
Jul 26	6
Jul 26	5.97
Jul 26	6.04
Jul 26	6.11
Jun 26	6.03
Jun 26	5.99
Jun 26	6.02
Jun 26	6.34
May 26	6.27
May 26	6.3
May 26	5.97
May 26	5.89
May 26	5.92
Apr 26	5.92
Apr 26	5.9
Apr 26	5.92
Apr 26	7.34
Mar 26	7.36
Mar 26	7.32
Mar 26	7.41
Mar 26	7.29
Feb 26	7.17
Feb 26	5.95
Feb 26	5.91
Feb 26	5.94
Jan 26	5.92
Jan 26	5.93
Jan 26	6.05
Jan 26	6.03
Jan 26	5.99
Dec 25	5.96
Dec 25	5.99
Dec 25	5.98
Dec 25	6.03
Nov 25	6.05
Nov 25	6.09
Nov 25	7.2
Nov 25	7.23
Oct 25	7.48
Oct 25	7.45
Oct 25	7.43
Oct 25	7.45
Oct 25	7.37
Sep 25	7.4
Sep 25	7.38
Sep 25	7.38
Sep 25	7.39
Aug 25	7.41
Aug 25	7.39
Aug 25	7.4
Aug 25	7.44
Aug 25	7.48
Jul 25	6.7
Jul 25	6.81
Jul 25	5.54
Jul 25	5.51
Jun 25	5.53
Jun 25	6.04
Jun 25	5.36
Jun 25	5.44
May 25	5.21
May 25	5.2
May 25	4.31
May 25	5.7
May 25	5.67
Apr 25	5.64
Apr 25	5.64
Apr 25	5.64
Apr 25	6.56
Mar 25	14.22
Mar 25	14.25
Mar 25	14.15
Mar 25	14.23
Feb 25	14.85
Feb 25	12.25
Feb 25	12.22
Feb 25	11.42
Jan 25	11.39
Jan 25	11.7
Jan 25	12.68
Jan 25	12.71
Jan 25	12.63
Dec 24	17
Dec 24	16.99
Dec 24	16.87
Dec 24	16.06
Nov 24	19.38
Nov 24	19.14
Nov 24	20.04
Nov 24	19.66
Nov 24	18.91
Oct 24	19.26
Oct 24	19.13

Price to Book

GIFLF Price to Book by quarter
Period	Price to Book
Sep 26	0.83
Sep 26	0.81
Aug 26	0.87
Aug 26	0.86
Aug 26	0.87
Aug 26	0.87
Jul 26	0.76
Jul 26	0.78
Jul 26	0.77
Jul 26	0.78
Jul 26	0.79
Jun 26	0.83
Jun 26	0.82
Jun 26	0.83
Jun 26	0.87
May 26	0.86
May 26	0.87
May 26	0.82
May 26	0.81
May 26	0.82
Apr 26	0.82
Apr 26	0.81
Apr 26	0.82
Apr 26	1.01
Mar 26	1.01
Mar 26	1.01
Mar 26	1.02
Mar 26	1
Feb 26	0.99
Feb 26	0.89
Feb 26	0.89
Feb 26	0.89
Jan 26	0.89
Jan 26	0.89
Jan 26	0.91
Jan 26	0.9
Jan 26	0.9
Dec 25	0.89
Dec 25	0.9
Dec 25	0.9
Dec 25	0.9
Nov 25	0.91
Nov 25	0.91
Nov 25	1.08
Nov 25	1.08
Oct 25	1.09
Oct 25	1.08
Oct 25	1.08
Oct 25	1.08
Oct 25	1.07
Sep 25	1.08
Sep 25	1.07
Sep 25	1.07
Sep 25	1.07
Aug 25	1.08
Aug 25	1.07
Aug 25	1.08
Aug 25	1.08
Aug 25	1.09
Jul 25	0.97
Jul 25	0.99
Jul 25	0.8
Jul 25	0.8
Jun 25	0.8
Jun 25	0.88
Jun 25	0.78
Jun 25	0.79
May 25	0.76
May 25	0.75
May 25	0.62
May 25	0.6
May 25	0.59
Apr 25	0.59
Apr 25	0.59
Apr 25	0.59
Apr 25	0.69
Mar 25	0.97
Mar 25	0.97
Mar 25	0.96
Mar 25	0.97
Feb 25	1.01
Feb 25	0.83
Feb 25	0.83
Feb 25	0.78
Jan 25	0.77
Jan 25	0.8
Jan 25	0.86
Jan 25	0.86
Jan 25	0.86
Dec 24	0.82
Dec 24	0.82
Dec 24	0.81
Dec 24	0.77
Nov 24	0.93
Nov 24	0.92
Nov 24	0.97
Nov 24	0.95
Nov 24	0.91
Oct 24	0.93
Oct 24	0.92

No video analysis for this stock yet. Request one from our team.

News: GIFLF

seekingalpha.com · 15 Aug 2026

Oakmark International Small Cap Strategy Q2 2026 Portfolio Update

The portfolio's return was 5.34% (net) for the reporting period. We initiated the following positions: Birkenstock Holding, Dormakaba, Hiab, Reply, SATS Ltd., and Scout24. We eliminated the following positions: Grifols Cl B ADR and Sopra Steria Group.

seekingalpha.com · 3 Jul 2026

Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)

First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.

globenewswire.com · 15 Jun 2026

Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.

BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or afibrinogenemia, FESILTY™ (fibrinogen, human-chmt) is now available in the U.S. FESILTY is not indicated for dysfibrinogenemia.